New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:04 EDTQCORQuestcor weakness attributed to change in CDF funding
The Chronic Disease Fund, or CDF, indicates on its website that funding for Nephrotic Syndrome is currently closed for new enrollments. Questcor, whose Acthar gel is indicated for the treatment of Nephrotic Syndrome, is down over 6% to $49.48 in early trading. Reference Link
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
13:13 EDTQCOREinhorn bought Lam Research shares, sold Rite Aid last quarter
Subscribe for More Information
12:18 EDTQCORGreenlight discloses short positions in Safeway, Questcor, Bloomberg says
Subscribe for More Information
10:02 EDTQCOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTQCORQuestcor downgraded to Perform from Outperform at Oppenheimer
July 24, 2014
09:10 EDTQCORQuestcor expects insurance coverage for Acthar to remain favorable, consistent
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 H.P. Acthar gel sales up 39% to $188.5M
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 adjusted EPS $1.85, consensus $1.74
Subscribe for More Information
July 21, 2014
07:36 EDTQCORMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use